BioSpace: Icosavax Turns VLP Tech to COVID-19 Vaccine, with $16.5 Million in New Financing

Icosavax is turning its virus-like particle (VLP) technology to fight COVID-19. The news accompanies $16.5 million in new funding from the Bill and Melinda Gates Foundation and Open Philanthropy, and the publication of preclinical data in Cell.

BioSpace’s Gail Dutton caught up with Icosavax CEO Adam Simpson to discuss its new vaccine candidate, IVX-411 — read the interview here.